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Bipolar disorder (BP) is a severe psychiatric disease, with a strong genetic component, that affects 1% of the
population worldwide and is characterized by recurrent episodes of mania and depression. Brain-derived neuro-
trophic factor (BDNF) has been implicated in the pathogenesis of mood disorders, and the aim of the present study
was to test for the presence of linkage disequilibrium between two polymorphisms in the BDNF gene and BP in
283 nuclear families. Family-based association test (FBAT) results for the dinucleotide repeat (GT)N polymorphism
at position 51040 bp showed that allele A3 was preferentially transmitted to the affected individuals (Zp
and ). FBAT results for the val66met SNP showed a significant association for allele G (2.035 Pp .042 Zp
and ). Transmission/disequilibrium test (TDT) haplotype analysis showed a significant result for3.415 Pp .00064
the 3-G allele combination ( ), suggesting that a DNA variant in the vicinity of the BDNF locus confersPp .000394
susceptibility to BP. Given that there is no direct evidence that either of the polymorphisms we examined alters
function, it is unlikely that the actual risk-conferring allele is from these two sites. Rather, the causative site is likely
nearby and in linkage disequilibrium with the 3-G haplotype that we have identified.
Family, adoption, and twin studies (Craddock and Jones
1999) have shown that bipolar disorder (MAFD1 [MIM
125480]) has a strong genetic component, and a non-
Mendelian mode of inheritance, with more than one gene
involved (McGuffin and Katz 1989; Gershon 1990). An-
imal studies have shown that brain-derived neurotrophic
factor (BDNF) is implicated in adapting to stress exposure
and in antidepressant response. Depressive states in ani-
mal models show a short- and long-term decrement in
levels of BDNF in the hippocampus (Nibuya et al. 1995;
Smith et al. 1995).
Recent reports indicate that antidepressant treatments,
including electroconvulsive therapy, induce the expression
of brain neurotrophins (Duman et al. 1998), suggesting
that neurotrophin production in the brain in depressed
patients may be deficient. Further evidence for the in-
volvement of neurotrophins, and particularly for BDNF
in depression, comes from studies in rats. BDNF was re-
ported to promote the function and growth of serotonin
(5-HT) neurons in the brain (Mamounas et al. 1999), and
infusion of BDNF in the adult rat brain induced sprouting
of 5-HT nerve terminals. (Siuciak et al. 1994, 1996). This
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is of particular relevance, because, in major mood dis-
orders, there is a decrease in brain 5-HT turnover in tissue
and ventricular fluids. BDNF, being lipophobic and a rel-
atively large protein, does not cross the blood-brain bar-
rier. Therefore, 5-HT receptors, phosphodiesterase inhi-
bition, and b-adrenoceptors appear to be implicated in
the neuronal production of BDNF in some brain areas
(Nibuya et al. 1995; Duman et al. 1997). Given that the
principal treatment of depressive states in mood disorders
consists of pharmacotherapy with selective serotonin
reuptake inhibitors (SSRIs) and that BDNF plays a sig-
nificant role in serotonin system development, the BDNF
gene becomes an important candidate in mood disorders.
The BDNF gene (BDNF [MIM 113505]) was first
reported, by Mainsonpierre et al. (1991) and Ozcelik et
al. (1991), to be localized on the short arm of chro-
mosome 11 (11p13) and was later mapped, by Hanson
et al. (1992), at the boundary of 11p13 and 11p14.
Linkage studies of the 11p region in BP have yielded
mostly negative results, with notable exceptions that in-
clude a nonparametric LOD score of 1.89 in the 11p13-
15 region (Detera-Wadleigh et al. 1999) and suggestive
LOD scores (as high as 1.95) in the same region for BP
in Costa Rican families (McInnes et al. 1996).
A valuable approach in the study of a disease with a
complex mode of inheritance is the use of linkage dis-
equilibrium (LD) analysis (Risch and Merikangas 1996),
in which a particular locus is tested in parent-proband
triads to detect association between the locus and the
disease in the presence of linkage (Knapp 1999). Two
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Table 1








1 .184 83 44.000 49.000 .953 .340
2 .030 13 5.000 7.000 1.000 .317
3 .700 93 135.000 123.750 2.035 .042
4 .065 40 17.000 20.250 1.038 .299
5 .009 5 … … … …
7 .003 3 … … … …
8 .004 0 … … … …
9 .004 3 … … … …
10 .002 1 … … … …
val66met:
A .231 115 51.000 73.000 3.415 .00064
G .769 115 185.000 163.00 3.415 .00064
a Number of informative families (i.e., families with at least one heterozygous parent).
b Test statistic from FBAT for the observed number of transmitted alleles.
c Expected value of S under the null hypothesis (i.e., no linkage or association).
d One-tailed.
hundred eighty-three probands (119 men and 164
women) with a primary diagnosis of bipolar I (Np
), bipolar II ( ), or schizoaffective disorder,182 Np 100
manic type ( ), mean age 34.2 years (SD 10.00),Np 11
andmean age at onset of the illness 19.69 years (SD 7.34),
were recruited, with their living parents, from hospital
clinics and through newspaper advertisements in Toronto
and across central Canada. Two hundred sixty-nine pro-
bands (95.0%) were of European origin, seven (2.5%)
were Asian, four (1.4%) were Native American (aborig-
inal), and three (1.1%) were African American. The study
was approved by the Research Ethics Board of the Centre
for Addiction and Mental Health in Toronto. From all
patients and their parents, written informed consent to
participate in the study was obtained.
Blood (20 ml) was drawn from each subject, andDNA
was extracted by use of the high-salt method (Lahiri and
Nurnberger 1991). Subjects were genotyped for the
BDNF dinucleotide-repeat polymorphism located 1,040
bp upstream from the transcription start site of the 1.6-
kb BDNF mRNA (Proschel et al. 1992), and for the
val66met SNP that determines a valine-to-methionine
substitution at position 66 in the coding region. PCR
was performed on 150 ng of template DNA to amplify
a fragment containing the dinucleotide-repeat polymor-
phism in the putative promoter region of the BDNF gene.
PCR products were subjected to electrophoresis on a 6%
denaturing polyacrylamide gel for 2 h, after which the
DNA was transferred to Whatman paper and exposed
to x-ray film for 30 min. DNA bands were assigned allele
numbers according to their size (allele 1p 174 bp; allele
2 p 172 bp; allele 3 p 170 bp; allele 4 p 168; and
allele 5 p 166).
The SNP for the GrA (valinermethionine) variation
at position 758 of the BDNF coding sequencewas selected
from the National Center for Biotechnology Information
SNP database (reference number rs6265). A 113-bp
segment was amplified by PCR, using the following
primers: 5′-GAGGCTTGACATCATTGGCT-3′ and 5′-
CGTGTACAAGTCTGCGTCCT-3′. Target sequences
were amplified in a 25-ml reaction solution containing
125 ng genomic DNA; 1 U Taq polymerase (Sigma-Al-
drich); 20 mM Tris-HCl (pH 8.4); 50 mM KCl; 1.5 mM
MgCl2; 200 mM each of dATP, dCTP, dGTP, and dTTP;
and 10 pmol of each primer. After an initial denaturation
of the DNA templates for 5 min at 95C, 30 cycles were
performed, each consisting of 94C for 30 s, 60C for 30
s, and 72C for 30 s. After the last cycle, samples were
incubated at 72C for 5 min. Samples were then digested
overnight with 3 U of Eco721 (MBI Fermentas). The
fragments were separated on a 3.5% agarose gel at 100
V, and fragments were visualizedwith ethidiumbromide.
The uncut product size was 113 bp (allele A), and allele
G comprised the cut bands of 78 and 35 bp.
We tested for presence of LD between both BDNF
polymorphisms and BP, using the family-based associ-
ation test (FBAT), which allows for inclusion of both
triads and extended families in the analysis. Transmis-
sion/disequilibrium test (TDT) for marker haplotypes
(GENEHUNTER, version 2.1) was used to test trans-
mission disequilibrium between haplotypes of the two
BDNF polymorphisms and BP. In our sample, we found
four common alleles of the dinucleotide-repeat poly-
morphism of the BDNF gene (A1p 18.5%, A2p 3%,
A3p 70.0%, and A4p 6%), with a heterozygosity of
47%. The total sample was in Hardy-Weinberg equilib-
rium when the rare genotypes were removed. The FBAT
results (table 1) showed an excess transmission of allele
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Table 2
Results of Haplotype Analysis Using TDT
Haplotype Translated Untranslated x2 P
1 A 20 39 6.12 .013376
1 G 8 8 .00 1.000000
2 A 0 1 1.00 .317311
2 G 6 8 .29 .592980
3 A 8 18 3.85 .049860
3 G 73 36 12.56 .000394
4 A 0 4 4.00 .045500
4 G 12 14 .15 .694887
5 G 2 2 .00 1.000000
7 G 1 1 .00 1.000000
10 A 1 0 1.00 .317311
A3 from parents to the offspring ( ). We alsoPp .042
tested for parent sex–specific transmission, but no par-
ent-of-origin effect was detected in the transmission of
BDNF alleles. Frequencies for the alleles of the val66met
polymorphism were Ap 23.1% and Gp 76.9%. FBAT
analysis of this SNP showed ( )Zp 3.415 Pp .00064
(table 1). Haplotype analysis, using TDT, resulted in
( ) for the 3-G combination (ta-2x p 12.56 Pp .00039
ble 2). An examination of the sample for association
between the presence/absence of risk haplotype and age
at onset, presence of psychotic symptoms, and rapid cy-
cling did not yield significant results. The 1-A haplotype
had significantly decreased transmission to probands
with BP, suggesting the possibility that it is protective
against the disorder. The degree of LD between the two
markers, as determined by the two-locus LD program
(Klitz et al. 1995), generated a D′ value of 0.695 for the
3-G haplotype and of 0.773 for A1, with a global dis-
equilibrium (3 df; ). The size2 7x p 822.25 P ! 1 # 10
of our sample is large enough to guarantee reasonable
power for the LD analysis performed (McGinnis 2000).
The present study is the largest to date of BDNF and
mood disorder. The results strongly suggest LD between
both the GT repeat and val66met markers and BP. The
presence of LD between BDNF and BP implies, in turn,
that this locus may be involved in the pathogenesis of
the disease. Further evidence for a role of BDNF in bi-
polar disorder has been reported by Sklar et al. (2002).
Brain imaging studies of patients with BP and unipolar
depression have demonstrated morphometric changes
that suggest cortical atrophy and/or cell death in these
patients (Elkis et al. 1995; Sheline et al. 1996, 1999;
Drevets et al. 1997, 1999; Soares et al. 1997; Steffens
et al. 1998). BDNF is a neurotrophin found primarily
in the neocortex, hippocampus, and amygdala (Buch-
man and Davies 1993; Ip et al. 1993; Korsching 1993;
Duman 1999). Most of the work, to date, that supports
the role of BDNF in depression has been derived from
studies in animals. BDNF may be implicated in the eti-
ology of BP in humans by affecting the mechanisms in-
volved in cell formation, cell death, and/or neuroplas-
ticity. BDNF is only one molecule among many others,
such as glutamate, that might be implicated in neuronal
survival (Moghaddam et al. 1994).
Because BP overlaps extensively with other mood dis-
orders, including unipolar depression, our significant
findings with BDNF may be applicable to depression in
general (King et al. 2001). Given the overlap of bipolar
disorder and schizophrenia in some genetic linkage stud-
ies, the question arises as to whether BDNF also plays
a role in schizophrenia. The BDNF (GT)n dinucleotide
repeat has been tested for association with schizophrenia
in six independent studies (Sasaki et al. 1997; Hawi et
al. 1998; Wassink et al. 1999; Krebs et al. 2000; Virgos
et al. 2001; Muglia et al. [in press]). Three of these
studies (Sasaki et al. 1997; Krebs et al. 2000; Virgos et
al. 2001) used a case-control association strategy, two
studies (Wassink et al. 1999; Muglia et al. [in press])
used a family-based approach, and a fifth study used
both the family and the case-control approach (Hawi et
al. 1998). Among these studies, none detected associa-
tion between the BDNF dinucleotide repeat and schizo-
phrenia, except the work reported in the article byMug-
lia et al. (in press). It is possible that our schizophrenia
sample, compared with others published, gave different
results because we included subjects with schizoaffective
disorder, depressed subtype, and because we focused on
a primarily Italian sample. In another phenotypic vari-
ation, Krebs and colleagues (2000) reported the presence
of an association between a group of BDNF-dinucleo-
tide long alleles (172–176 bp) and patients with late-
onset schizophrenia that responded to neuroleptics.
Overall, the data to date do not suggest a strong overlap
in the effect of BDNF between bipolar disorder and
schizophrenia. Depression, in turn, is the most common
of all the psychiatric disorders, and it represents one of
the leading health problems worldwide (Murray and
Lopez 1997), along with cardiovascular and infectious
diseases. Thus, if the positive associations of BDNF in
mood disorders can be replicated, the relevance to world
health may be highly significant.
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